financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
Scilex Holding Venture Initiates Trial Enrollment for Alzheimer's Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Scilex Holding Venture Initiates Trial Enrollment for Alzheimer's Treatment
Dec 11, 2024 10:37 AM

01:11 PM EST, 12/11/2024 (MT Newswires) -- Scilex Holding's ( SCLX ) Scilex Bio venture with IPMC said Wednesday it is enrolling patients with Alzheimer's disease showing mild cognitive impairment and mild dementia in the phase 2 study of KDS2010.

The company is currently enrolling 114 subjects in South Korea and enrollment of the US cohort will begin in 2025, Scilex Bio said.

Scilex Bio said it will evaluate the safety and efficacy of the drug in the randomized, double-blind, placebo-controlled study.

IPMC is a representative company of the Bio Innovation Consortium, which holds exclusive rights to NeuroBiogen's KDS2010 global license.

Price: 0.56, Change: -0.01, Percent Change: -2.59

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nano Nuclear Energy Prices Upsized $18 Million Offering; Shares Down Pre-Bell
Nano Nuclear Energy Prices Upsized $18 Million Offering; Shares Down Pre-Bell
Jul 12, 2024
07:37 AM EDT, 07/12/2024 (MT Newswires) -- Nano Nuclear Energy ( NNE ) said Friday it priced its underwritten public offering of 900,000 common shares and warrants to purchase 450,000 common shares at $20 each for gross proceeds of about $18 million. The underwriter has been granted a 30-day option to purchase up to an additional 135,000 shares and/or associated...
 Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Jul 12, 2024
Friday, Immutep Limited ( IMMP ) released results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial of eftilagimod alfa (efti) in combination with Merck & Co Inc ( MRK ) Keytruda (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. The updated efficacy and safety data was presented...
 Top Premarket Gainers
Top Premarket Gainers
Jul 12, 2024
07:37 AM EDT, 07/12/2024 (MT Newswires) -- Crown LNG Holdings (CGBS) shares nearly doubled Friday premarket following a 22% drop in the previous session. Sentage Holdings ( SNTG ) shares surged 33% after Thursday's 4.6% increase. Instil Bio ( TIL ) shares increased 17% after the company said it secured AstraZeneca as a tenant at its California facility. Immutep (...
 Unilever to cut a third of office jobs in Europe, FT reports
Unilever to cut a third of office jobs in Europe, FT reports
Jul 12, 2024
(Reuters) - Unilever ( UL ) plans to cut a third of all office roles in Europe by the end of next year as new CEO Hein Schumacher forges ahead with a plan to boost growth at the struggling consumer goods giant, the Financial Times reported on Friday. The company told senior executives on Wednesday that as many as 3,200...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved